- Home
- MFIN vs ALLO Comparison
MFIN vs ALLO Comparison
Compare MFIN & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- ALLO
- Stock Information
- Founded
- MFIN 1995
- ALLO 2017
- Country
- MFIN United States
- ALLO United States
- Employees
- MFIN N/A
- ALLO N/A
- Industry
- MFIN Finance: Consumer Services
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MFIN Finance
- ALLO Health Care
- Exchange
- MFIN Nasdaq
- ALLO Nasdaq
- Market Cap
- MFIN 243.9M
- ALLO 252.9M
- IPO Year
- MFIN 1996
- ALLO 2018
- Fundamental
- Price
- MFIN $9.83
- ALLO $1.15
- Analyst Decision
- MFIN Strong Buy
- ALLO Buy
- Analyst Count
- MFIN 1
- ALLO 12
- Target Price
- MFIN $12.00
- ALLO $8.80
- AVG Volume (30 Days)
- MFIN 39.1K
- ALLO 2.5M
- Earning Date
- MFIN 10-29-2025
- ALLO 11-06-2025
- Dividend Yield
- MFIN 4.92%
- ALLO N/A
- EPS Growth
- MFIN 1.06
- ALLO N/A
- EPS
- MFIN 1.71
- ALLO N/A
- Revenue
- MFIN $338,783,000.00
- ALLO N/A
- Revenue This Year
- MFIN N/A
- ALLO N/A
- Revenue Next Year
- MFIN $3.82
- ALLO $100.00
- P/E Ratio
- MFIN $5.71
- ALLO N/A
- Revenue Growth
- MFIN 15.52
- ALLO N/A
- 52 Week Low
- MFIN $7.71
- ALLO $0.86
- 52 Week High
- MFIN $10.98
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- MFIN 48.12
- ALLO 44.43
- Support Level
- MFIN $9.26
- ALLO $1.05
- Resistance Level
- MFIN $10.20
- ALLO $1.28
- Average True Range (ATR)
- MFIN 0.32
- ALLO 0.07
- MACD
- MFIN 0.03
- ALLO -0.02
- Stochastic Oscillator
- MFIN 59.22
- ALLO 37.50
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.